Skip to content
Screener

Summit Therapeutics SMMT Q4 2025 Annual earnings

Reported February 23, 2026 · After market close

EPS-$0.29Miss by $0.19
Revenue estimate$56.8M
EPS estimate-$0.10

Next report

Oct 19, 2026 (in 2 months)
Revenue estimate$71.4K
EPS estimate-$0.28

Financials

Q4 2025

Income statement

See full
Net income-$219.2M-258%
EPS (diluted)-$0.28-211%

Balance sheet

See full
Cash & equivalents$16.4M+0.6%
Total debt$20.9M+189%
Total equity$658.9M+69.5%
Total assets$751.2M+72.5%

Cash flow

See full
Operating cash flow-$101.9M-109%
CapEx$164.0K+1,071%
Free cash flow-$102.1M-110%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$13.02B-1.1%
Enterprise value$13.02B-1.0%

Returns & leverage

See full
Return on equity-206.1%-1,405pp
Debt / equity0×0.0×
Current ratio9.9×-0.3×

FAQ

When did Summit Therapeutics report Q4 2025 earnings?
Summit Therapeutics (SMMT) reported Q4 2025 earnings on February 23, 2026 after market close.
What were Summit Therapeutics's Q4 2025 revenue and EPS?
Summit Therapeutics reported eps of $-0.29 for Q4 2025.
Did Summit Therapeutics beat estimates in Q4 2025?
EPS missed the consensus estimate of $-0.10 by $0.19.
How did Summit Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 262.5% from $-0.08.
Where can I find Summit Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001599298-26-000014) and the 10-K periodic report (0001599298-26-000015) directly on SEC EDGAR. The filing index links above go to sec.gov.